Morepen Laboratories Limited has informed the Exchange regarding a press release dated May 27, 2026, titled "Morepen Labs Q4 Net Profit Rises 69%; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10% to the shareholders for FY26.".
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Morepen Laboratories reported a strong Q4 FY26 with net profit up 69% YoY to Rs. 20 crore and gross revenue up 22% YoY to Rs. 472 crore. The API business grew 17% while Medical Devices surged 31% during the quarter. For the full year FY26, standalone gross revenue crossed Rs. 1,700 crore, up 8% YoY. The company commenced commercial production under its Rs. 825 crore (USD 91 million) global CDMO mandate received from a leading multinational, marking a shift toward long-duration manufacturing partnerships. EBITDA stood at Rs. 32 crore vs Rs. 33 crore in Q4 FY25, reflecting near-term investments in capacity expansion (from ~500 KL to ~800 KL) and Medical Devices growth. The board proposed a 10% dividend for FY26. The company also completed a pivotal bioequivalence study for Resmetirom 100 mg and passed its 4th consecutive USFDA inspection with zero 483 observations.
Strong Q4 profit growth and a new commercial CDMO program signal positive momentum. The near-term EBITDA compression from investment spending is expected to yield operating leverage and margin expansion going forward. The dividend proposal adds a positive signal for shareholders.